Literature DB >> 14656279

Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy.

B Sorbe1.   

Abstract

In a prospective randomized trial, consolidation treatment with radiotherapy or chemotherapy was compared with no treatment in a series of 172 patients with epithelial ovarian carcinoma, FIGO stage III, with complete surgical remission after primary cytoreductive surgery and induction chemotherapy. In the subgroup with complete pathological remission, progression-free survival (PFS) was significantly (P = 0.032) better in the radiotherapy group (56%) than in the chemotherapy group (36%) and the untreated control group (35%). The number of recurrences was lowest in the radiotherapy group. The overall relapse rate was reduced by 33% and the pelvic recurrences by 43% by consolidation radiotherapy. On the other hand, treatment-related side effects were more frequent in the radiotherapy group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656279     DOI: 10.1111/j.1525-1438.2003.13359.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.

Authors:  Lisa M Hess; Nan Rong; Patrick O Monahan; Paridha Gupta; Champ Thomaskutty; Daniela Matei
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

Review 2.  Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Authors:  Rachel N Grisham; Jonathan Berek; Jacobus Pfisterer; Paul Sabbatini
Journal:  Immunotherapy       Date:  2011-02       Impact factor: 4.196

3.  Consolidation strategies in ovarian cancer: observations for future clinical trials.

Authors:  Paul Sabbatini; David Spriggs; Carol Aghajanian; Martee Hensley; William Tew; Jason Konner; Kathryn Bell-McGuinn; Margrit Juretzka; Alexia Iasonos
Journal:  Gynecol Oncol       Date:  2010-01       Impact factor: 5.482

4.  Current status of maintenance therapy for advanced ovarian cancer.

Authors:  Joanie Mayer Hope; Stephanie V Blank
Journal:  Int J Womens Health       Date:  2010-08-09

5.  Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

Authors:  Paul Sabbatini; Philipp Harter; Giovanni Scambia; Jalid Sehouli; Werner Meier; Pauline Wimberger; Klaus H Baumann; Christian Kurzeder; Barbara Schmalfeldt; David Cibula; Mariusz Bidzinski; Antonio Casado; Andrea Martoni; Nicoletta Colombo; Robert W Holloway; Luigi Selvaggi; Andrew Li; Jose del Campo; Karel Cwiertka; Tamas Pinter; Jan B Vermorken; Eric Pujade-Lauraine; Simona Scartoni; Monica Bertolotti; Cecilia Simonelli; Angela Capriati; Carlo Alberto Maggi; Jonathan S Berek; Jacobus Pfisterer
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

6.  Dose-dense chemotherapy improves mechanisms of antitumor immune response.

Authors:  Chih-Long Chang; Yun-Ting Hsu; Chao-Chih Wu; Yan-Zen Lai; Connie Wang; Yuh-Cheng Yang; T-C Wu; Chien-Fu Hung
Journal:  Cancer Res       Date:  2012-10-29       Impact factor: 12.701

7.  Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification.

Authors:  Jing Shen; Yin Jie Tao; Hui Guan; Hong Nan Zhen; Ting Ting Dong; Zhi Kai Liu; Fu Quan Zhang
Journal:  World J Oncol       Date:  2022-06-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.